Breaking News

Tesa Labtec Completes FDA Inspection

February 25, 2016

Milestone supports expansion plans to the U.S. market

Tesa Labtec, a German patch and oral thin film maker, has completed a Pre-Approval Inspection (PAI) by the U.S. FDA in February 2016. The PAI was triggered by a customer’s ANDA filing for a transdermal patch, which is manufactured by tesa and is designated for U.S. distribution.

The FDA visited both the R&D site in Langenfeld as well as the manufacturing facility in Hamburg, Germany. FDA provided feedback with a short list of observations, which the company plans to promptly address. The FDA Investigator said that the initial conclusion was to approve the sites for commercial activities, which must still be reviewed by the FDA.

“This FDA inspection demonstrates a significant milestone within our plan to expand our business to the U.S. market,” said Dr. Ingo Lehrke, managing director of tesa Labtec. “The inspection paves the way to the U.S. market for our customers’ transdermal patches and oral thin films and certifies the high quality of our development and manufacturing capabilities. This achievement was made possible through the dedication of our talented staff.”

Related Contract Manufacturing:

Related Compliance:

  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks